Notably, 58.1% of tonsil cancers harbored candidate target mutations in 14 genes (ALK, ATM, EGFR, ERBB2, FGFR3, FLT3, IDH1, IDH2, KIT, KRAS, MET, PDGFRA, PIK3CA, and SMARCB1) with level 1 evidence in OncoKBTM, which could be implicated in targeted therapies in the future. This evidence concerns the gene SMARCB1 and cancer.